ridm@nrct.go.th   ระบบคลังข้อมูลงานวิจัยไทย   รายการโปรดที่คุณเลือกไว้

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

หน่วยงาน มหาวิทยาลัยเชียงใหม่

รายละเอียด

ชื่อเรื่อง : Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
นักวิจัย : Wang Y. , Thongsawat S. , Gane E.J. , Liaw Y.-F. , Jia J. , Hou J. , Chan H.L.Y. , Papatheodoridis G. , Wan M. , Niu J. , Bao W. , Trylesinski A. , Naoumov N.V.
คำค้น : -
หน่วยงาน : มหาวิทยาลัยเชียงใหม่
ผู้ร่วมงาน : -
ปีพิมพ์ : 2556
อ้างอิง : 13520504 , 10.1111/jvh.12025 , 23490388 , JVHEE , http://www.scopus.com/inward/record.url?eid=2-s2.0-84875229260&partnerID=40&md5=1eda83af67c7ccfd0971bbc62d162056 , http://www.ncbi.nlm.nih.gov/pubmed/23490388 , http://cmuir.cmu.ac.th/handle/6653943832/4045
ที่มา : -
ความเชี่ยวชาญ : -
ความสัมพันธ์ : -
ขอบเขตของเนื้อหา : -
บทคัดย่อ/คำอธิบาย :

In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%) of telbivudine-treated patients, who were serum HBV DNA positive or negative and without genotypic resistance to telbivudine at the end of the GLOBE/015 trials, were enrolled into a further 2-year extension study. A group of 502 patients completed 4 years of continuous telbivudine treatment and were included in the telbivudine per-protocol population. Amongst 293 HBeAg-positive patients, 76.2% had undetectable serum HBV DNA and 86.0% had normal serum ALT at the end of 4 years. Notably, the cumulative rate of HBeAg seroconversion was 53.2%. Amongst 209 HBeAg-negative patients, 86.4% had undetectable HBV DNA and 89.6% had normal serum ALT. In patients who had discontinued telbivudine treatment due to HBeAg seroconversion, the HBeAg response was durable in 82% of patients (median 111 weeks of off-treatment follow-up). The cumulative 4-year resistance rate was 10.6% for HBeAg-positive and 10.0% for HBeAg-negative patients. Most adverse events were mild or moderate in severity and transient. Renal function measured by estimated glomerular filtration rate (eGFR) increased by 14.9 mL/min/1.73 m2 (16.6%) from baseline to 4 years (P < 0.0001). In conclusion, in HBeAg-positive and HBeAg-negative CHB patients without resistance after 2 years, two additional years of telbivudine treatment continued to provide effective viral suppression with a favourable safety profile. Moreover, telbivudine achieved 53% of HBeAg seroconversion in HBeAg-positive patients. © 2012 Blackwell Publishing Ltd.

บรรณานุกรม :
Wang Y. , Thongsawat S. , Gane E.J. , Liaw Y.-F. , Jia J. , Hou J. , Chan H.L.Y. , Papatheodoridis G. , Wan M. , Niu J. , Bao W. , Trylesinski A. , Naoumov N.V. . (2556). Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Wang Y. , Thongsawat S. , Gane E.J. , Liaw Y.-F. , Jia J. , Hou J. , Chan H.L.Y. , Papatheodoridis G. , Wan M. , Niu J. , Bao W. , Trylesinski A. , Naoumov N.V. . 2556. "Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B".
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Wang Y. , Thongsawat S. , Gane E.J. , Liaw Y.-F. , Jia J. , Hou J. , Chan H.L.Y. , Papatheodoridis G. , Wan M. , Niu J. , Bao W. , Trylesinski A. , Naoumov N.V. . "Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B."
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ , 2556. Print.
Wang Y. , Thongsawat S. , Gane E.J. , Liaw Y.-F. , Jia J. , Hou J. , Chan H.L.Y. , Papatheodoridis G. , Wan M. , Niu J. , Bao W. , Trylesinski A. , Naoumov N.V. . Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ ; 2556.